ICICI Securities Limited Broker Research reports

NTPC – the largest thermal power player in India, is looking to add shades of green to its portfolio. It has substantial capacity addition plans on both thermal and renewables front.

Gravita India’s (GRAV) performance was in-line with consensus estimates. The company reported EBITDA at INR 1bn (+15%/+9% YoY/QoQ) driven by, total volumes rising 12.4% YoY to 53.4Kte (flat YoY), better margins at the lead segment (INR 21,790/te; up 13%/7% YoY/QoQ), as GRAV used higher imported material that fetched better pricing.

Larsen & Toubro (L&T) continues to beat order inflow (OI) expectations. It secured INR 766bn worth of orders in its core businesses (ex-services), up 40% YoY – aided by the energy (3.5x YoY; 41% of OI) and infrastructure (+2% YoY; 53% QoQ) segments.

Adani Green Energy (AGEL) started FY26 on a strong note, posting a strong quarter on both operational and financial fronts. It commissioned ~1.6GW in Q1FY26, taking operational capacity to 15.8GW (+45% YoY).

GE Vernova (GE) reported a strong Q1FY26 performance, with revenue up 38% YoY to INR 13.1bn and EBITDA more than doubling to INR 3.8bn. The standout was the sharp 1,000bps expansion in EBITDA margin driven by higher contribution from exports.

ABD reported strong volume-led performance with driven by 44% growth in P&A segment, increasing its volume/ value saliency to 46%/ 56% from 37%/ 46% last year.

Railtel Corporation of India (Railtel) Q1FY26 adjusted net profit grew 2.8% YoY; and as expected revenue growth driven by projects business tends to drive profits slower.

Five Star Business Finance (Five Star)’s management attributes the company’s asset quality deterioration, stage3 assets increasing to 2.5% vs. 1.8% QoQ and 30+ DPD rising to 11.3% vs. 9.65% QoQ, to higher stress in its core product (INR 0.3–0.5mn LAP) in the near term.

Chemplast Sanmar (CSL) has been enduring challenges over the past two years due to a weak cycle in PVC business; finally, early signs of consolidation have surfaced, and policy action should aid business recovery.

Piramal Pharma’s (Piramal) Q1FY26 result was below our expectations. Performance was impacted due to lack of revenue from a large innovative CDMO (-5.7% YoY) molecule and delay in shipment timing in CHG business (grew 1%).